News
-
Hybrigenics Starts Phase II Clinical Trial Of Inecalcitol In Chronic Lymphocytic Leukemia
9/11/2012
Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext in Paris, with a focus on research and development of new treatments against proliferative diseases, recently announces the start of a phase II clinical trial of oral inecalcitol in patients with chronic lymphocytic leukemia (CLL).
-
Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration With AstraZeneca
9/10/2012
Palatin Technologies, Inc. (NYSE MKT: PTN) today announced that its collaboration partner, AstraZeneca, has decided to discontinue further development of AZD2820, one of a number of collaboration compounds in various stages of development for the treatment of obesity. AstraZeneca remains committed to this collaboration program and to the continued advancement of melanocortin agonists for treatment of obesity.
-
Merck Announces New Phase III Data For Suvorexant, An Investigational Insomnia Medicine
9/10/2012
Merck, known as MSD outside the United States and Canada, recently announced new data for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. The new data are from one of the longest, continuously-dosed, placebo-controlled trials of a sleep medication ever conducted.
-
Lilly Announces Results From Lung Cancer Study
9/7/2012
Eli Lilly and Company (NYSE: LLY) announced today that the Phase III POINTBREAK trial did not meet its primary endpoint of improved overall survival for patients with nonsquamous non-small cell lung cancer (NSCLC) who were randomized to receive a combination of ALIMTA® (pemetrexed for injection) with bevacizumab (AVASTIN®) and carboplatin induction followed by ALIMTA plus bevacizumab maintenance–the ALIMTA arm–compared to the combination of paclitaxel with bevacizumab and carboplatin followed by bevacizumab maintenance–the paclitaxel arm.
-
Third Critically Ill Patient Successfully Treated With Pluristem's PLX Cells Under Compassionate Use
9/5/2012
Pluristem Therapeutics, Inc. a leading developer of placenta-based cell therapies, announced recently that the Company’s Placental eXpanded (PLX) cells were successfully administered to a third patient at Hadassah Medical Center, following two other life saving compassionate use cases.
-
Quotient And Pulmatrix Announce Completion Of Innovative COPD Proof-Of-Concept Clinical Program
9/4/2012
Quotient Clinical, a leading provider of specialist early stage drug development services, and Pulmatrix, a clinical stage biotechnology company creating novel inhaled therapeutics, recently announced the completion of an early clinical program to achieve proof-of-concept data in COPD patients for PUR118, Pulmatrix’s lead iCALM (inhaled dry powder cationic airway lining modulator) therapeutic.
-
ImmusanT Initiates Clinical Trials Of Nexvax2 Therapeutic Vaccine For Celiac Disease
9/4/2012
ImmusanT announced recently that it has initiated clinical trials in New Zealand, Australia and the U.S. to evaluate Nexvax2, the first therapeutic vaccine for patients with celiac disease.
-
Pluristem Files For Orphan Drug Status With U.S. FDA For Use Of PLX Cells In Treatment Of Aplastic Anemia
8/30/2012
The filing marks Pluristem’s second orphan drug application to the U.S. FDA. The company applied once before, and successfully received in August of 2011, orphan drug status from the FDA for its PLX cell therapy in the treatment of Buerger’s disease.
-
Daiichi Sankyo And Lilly Announce TRILOGY ACS Results Regarding Effient (Prasugrel) In Acute Coronary Syndrome UA/NSTEMI Patients To Be Managed Medically Without An Artery-Opening Procedure
8/26/2012
Daiichi Sankyo Company, Limited, and Eli Lilly and Company recently announced data from the TRILOGY ACS study, a phase III trial comparing prasugrel plus aspirin to clopidogrel plus aspirin in patients with unstable angina (UA) or non-ST elevation myocardial infarction (NSTEMI), who were managed medically without an arteryopening procedure.
-
Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis
8/23/2012
Janssen Biologics (Ireland) announced today it has initiated the Phase 3 development program for sirukumab (CNTO 136) as part of a collaboration with GlaxoSmithKline plc (GSK).